Zhejing Pharmaceutical (688266.SH): Clinical trials of injection ZG005, injection ZGGS18, and Gefitinib Hydrochloride Tablets in combination for advanced solid tumors have been approved.

Intelligence Finance and Economics APP news, Zejing Pharmaceuticals (688266.SH) announced that the company recently received the "Notice of Approval of Clinical Trial of Drugs" issued by the National Medical Products Administration (referred to as "NMPA"). The clinical trial of injection ZG005, injection ZGGS18, and gefitinib hydrochloride tablets used in combination for late-stage solid tumors has been approved.